Published in Diagn Microbiol Infect Dis on August 01, 2004
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation. Eukaryot Cell (2007) 1.14
Comparative phenotypic analysis of the major fungal pathogens Candida parapsilosis and Candida albicans. PLoS Pathog (2014) 0.96
Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans. PLoS One (2011) 0.95
Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance. Biomed Res Int (2015) 0.88
Biology and genetics of the pathogenic yeast Candida parapsilosis. Curr Genet (2009) 0.86
Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. BMC Infect Dis (2015) 0.83
Isolates from hospital environments are the most virulent of the Candida parapsilosis complex. BMC Microbiol (2011) 0.83
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Investigation of an unrecognized large-scale outbreak of Candida parapsilosis sensu stricto fungaemia in a tertiary-care hospital in China. Sci Rep (2016) 0.78
Risk factors and predictors of mortality of candidaemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species. Infection (2017) 0.75
Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol (2001) 2.08
Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol (1992) 1.80
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Epidemiology and microbiology of surgical wound infections. J Clin Microbiol (2000) 1.67
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1999) 1.62
Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey. Infection (2003) 1.54
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol (2002) 1.51
Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med (2001) 1.48
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS (2001) 1.41
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia (1993) 1.38
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis (1995) 1.37
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother (1997) 1.35
A waterborne outbreak of leptospirosis. Am J Epidemiol (1987) 1.35
Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol (1998) 1.33
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother (2000) 1.28
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
Comparative evaluation of the MB-Check system for recovery of mycobacteria from clinical specimens. Eur J Clin Microbiol Infect Dis (1992) 1.23
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother (2001) 1.22
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother (1998) 1.22
Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Clin Infect Dis (1996) 1.22
Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin Infect Dis (1995) 1.21
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol (1995) 1.16
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Diagn Microbiol Infect Dis (1995) 1.15
Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection (2013) 1.14
Irritable bowel syndrome in patients with Blastocystis hominis infection. Eur J Clin Microbiol Infect Dis (1999) 1.14
Hepatitis A and B in children and adolescents--what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine (2000) 1.12
An outbreak of hepatitis A in Puglia, Italy, 1996. Euro Surveill (1996) 1.12
Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. Eur J Epidemiol (1999) 1.10
Epidemiologic features of intestinal parasitic infections in Italian mental institutions. Eur J Epidemiol (1997) 1.09
Is a kit for identification of clinical yeasts correctly evaluated when released onto the market? Eur J Clin Microbiol Infect Dis (2000) 1.09
In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother (1999) 1.06
National pathfinder survey on children's oral health in Italy: pattern and severity of caries disease in 4-year-olds. Caries Res (2009) 1.05
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol (1994) 1.04
A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection (2013) 1.04
Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother (2000) 1.03
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother (1999) 1.03
Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect (2005) 1.03
Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother (2000) 1.02
Electrophoretic karyotyping and triazole susceptibility of Candida glabrata clinical isolates. Eur J Clin Microbiol Infect Dis (1999) 1.02
Detection of hepatitis A virus in mussels from different sources marketed in Puglia region (South Italy). Int J Food Microbiol (2002) 1.01
Genotypic identification of sequential Candida albicans isolates from AIDS patients by polymerase chain reaction techniques. Eur J Clin Microbiol Infect Dis (1997) 1.00
Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother (1998) 1.00
Environmental and serological evidence for the presence of toxocariasis in the urban area of Ancona, Italy. Eur J Epidemiol (2000) 0.99
In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Antimicrob Agents Chemother (1998) 0.99
In vitro susceptibility tests for cationic peptides: comparison of broth microdilution methods for bacteria that grow aerobically. Antimicrob Agents Chemother (2000) 0.98
A persisting outbreak of hepatitis A in Puglia, Italy, 1996: epidemiological follow-up. Euro Surveill (1997) 0.98
Non-O1 Vibrio cholerae gastroenteritis and bacteraemia. Lancet (1991) 0.98
Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol (1993) 0.96
In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn Microbiol Infect Dis (2000) 0.95
Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Peptides (2000) 0.94
Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother (2009) 0.94
National Pathfinder survey of 12-year-old Children's Oral Health in Italy. Caries Res (2007) 0.94
Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol (1997) 0.94
Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia. J Chemother (2011) 0.93
In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol (2001) 0.93
In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. J Antimicrob Chemother (1997) 0.93
Prevalence of anti-legionella antibodies among Italian hospital workers. J Hosp Infect (2008) 0.93
Unusual clinical presentation of infection due to Flavimonas oryzihabitans. Eur J Clin Microbiol Infect Dis (1998) 0.92
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. J Antimicrob Chemother (1996) 0.92
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot. J Infect (1999) 0.92
Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. J Chemother (1992) 0.92
In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother (1999) 0.91
Effect of pentamidine on the growth of Cryptococcus neoformans. J Antimicrob Chemother (1994) 0.90
Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI. J Hosp Infect (2009) 0.90
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.88
Efficient identification of Malassezia yeasts by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Br J Dermatol (2014) 0.88
HBV, HCV and HDV infections in Albanian refugees in Southern Italy (Apulia region). Epidemiol Infect (2000) 0.88
In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. Antimicrob Agents Chemother (1999) 0.88
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. J Surg Res (2001) 0.87
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. J Med Microbiol (1999) 0.87
Electron microscope study of a case of Australia antigen-positive chronic hepatitis. J Clin Pathol (1973) 0.87
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2000) 0.86
Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture. Antimicrob Agents Chemother (2000) 0.86
Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates. Mycoses (1995) 0.86
Immunogenetic factors in thalassemia and hepatitis B infection. A multicentre study. Dev Biol Stand (1975) 0.86
Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J Antimicrob Chemother (2000) 0.86
Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management. Eur J Clin Microbiol Infect Dis (2000) 0.86
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection (2013) 0.86
Role of birds of prey as carriers and spreaders of Cryptococcus neoformans and other zoonotic yeasts. Med Mycol (2006) 0.85
Air sampling methods to evaluate microbial contamination in operating theatres: results of a comparative study in an orthopaedics department. J Hosp Infect (2011) 0.85
Cavernicolous habitats harbouring Cryptococcus neoformans: results of a speleological survey in Apulia, Italy, 1999-2000. Med Mycol (2003) 0.85
Direct detection of Clostridium perfringens enterotoxin in patients' stools during an outbreak of food poisoning. FEMS Immunol Med Microbiol (1999) 0.85
Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection. Antimicrob Agents Chemother (2000) 0.84
Leuconostoc citreum isolated from lung in AIDS patient. Lancet (1993) 0.84
Environmental surveillance of poliovirus in Italy: pilot study. Ann Ig (2003) 0.84
Behaviour of Listeria monocytogenes during the maturation of naturally and artificially contaminated salami: effect of lactic-acid bacteria starter cultures. Int J Food Microbiol (1993) 0.83
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. Gut (2003) 0.83
Allergy, asthma and markers of infections among Albanian migrants to Southern Italy. Allergy (2004) 0.83
Chronic cryptococcal meningitis in an intravenous drug addict without evidence of infection by HIV-1,2 in southern Italy. Eur J Epidemiol (1994) 0.82
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. Br J Dermatol (2009) 0.82
In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Am Rev Respir Dis (1992) 0.82
Seroimmunity to poliomyelitis in an Albanian immigrant population. Vaccine (1992) 0.82
A note on the isolation of Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol (2002) 0.82
Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Med Hyg (2011) 0.81